Helix BioPharma Corp
HBP
Company Profile
Business description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.
Contact
40 Temperance Street
Suite 2700, Bay Adelaide Centre - North Tower
TorontoONM5H0B4
CANT: +1 604 684-2181
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,232.80 | 57.70 | 0.71% |
| CAC 40 | 7,536.26 | 33.48 | 0.45% |
| DAX 40 | 22,242.45 | 177.94 | 0.81% |
| Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
| FTSE 100 | 8,415.25 | 7.81 | 0.09% |
| HKSE | 21,878.50 | 102.24 | -0.47% |
| NASDAQ | 17,382.94 | 216.90 | 1.26% |
| Nikkei 225 | 35,969.32 | 263.58 | 0.74% |
| NZX 50 Index | 12,148.49 | 130.65 | 1.09% |
| S&P 500 | 5,525.21 | 40.44 | 0.74% |
| S&P/ASX 200 | 8,026.70 | 58.50 | 0.73% |
| SSE Composite Index | 3,285.69 | 9.38 | -0.28% |